Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of vorinostat in treating
patients with metastatic or unresectable solid tumors or lymphoma and liver dysfunction.
(closed for accrual as of 04/05/2010) Vorinostat may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth. Vorinostat may have different effects in
patients who have changes in their liver function.